viewReNeuron Group PLC

ReNeuron to present data showing “significant advance” of CTX treatment

Data for the first time shows CTX could potentially produce non-donor-specific, 'off-the-shelf' stem cells as an alternative to existing treatments

Researcher using microscope
ReNeuron will present the data to the Annual Congress of the European Society of Gene and Cell Therapy

ReNeuron Group PLC (LON:RENE) will present new data for its CTX treatment showing what it says is a “significant advance” for the stem cell platform.

The biotech group said the data, to be presented on Wednesday at the Annual Congress of the European Society of Gene and Cell Therapy (ESGCT), shows for the first time that CTX can be used to produce new, non-donor-specific stem cells which are then used to develop therapies for diseases that currently have an unmet medical need.

READ: ReNeuron cell-based treatment hailed by leading non-profit group funding research into treatments for retinal degenerative diseases

Randolph Corteling, ReNeuron’s head of research, said the developments may also allow for the production of “off the shelf” non-donor stem cells, which could serve as an alternative to treatments such as cancer immunotherapies which rely on a patient’s own T-cells (cells in the body which fight illnesses).

The data will be presented at the conference in Barcelona by Steve Pells, ReNeuron’s principal investigator.

Quick facts: ReNeuron Group PLC

Price: 173 GBX

Market: LSE
Market Cap: £55.07 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ReNeuron Group PLC named herein, including the promotion by the Company of ReNeuron Group PLC in any Content on the Site, the Company receives...



ReNeuron signs retinal stem cell exclusivity agreement

ReNeuron Group Plc (LON:RENE) has inked a deal worth up to US$5mln ahead of potentially licensing out its ground-breaking its hRPC retinal stem cell technology and therapeutic programmes. CFO Michael Hunt says they're hoping the exclusivity agreement with an unnamed US-based speciality...

on 11/7/18

2 min read